Indirect treatment comparison of bevacizumab + interferon-α-2a vs tyrosine kinase inhibitors in first-line metastatic renal cell carcinoma therapy

References

• CoppinCPorzsoltFAwaAKumpfJColdmanAWiltTImmunotherapy for advanced renal cell cancerCochrane Database Syst Rev20043CD00142510908496
   PubMedGoogle Scholar
• Commission on Cancer, American Cancer Society. National Cancer Data Base (NCDB)2008 Available from: http://www.facs.org/cancer/ncdb/. Accessed 2010 Dec 6.
   Google Scholar
• NeseNPanerGPMallinKRitcheyJStewartAAminMBRenal cell carcinoma: assessment of key pathologic prognostic parameters and patient characteristics in 47,909 cases using the National Cancer Data BaseAnn Diagn Pathol20091311819118775
   PubMed Web of Science ®Google Scholar
• GarciaJARiniBIRecent progress in the management of advanced renal cell carcinomaCA Cancer J Clin200757211212517392388
   PubMed Web of Science ®Google Scholar
• MickischGHRational selection of a control arm for randomised trials in metastatic renal cell carcinomaEur Urol200343667067912767369
   PubMed Web of Science ®Google Scholar
• EscudierBBellmuntJNegrierSFinal results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-alpha-2a (IFN) in metastatic renal cell carcinoma (mRCC): Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2009 May 29–Jun 2J Clin Oncol20092715S5020
   Google Scholar
• MotzerRJHutsonTETomczakPOverall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinomaJ Clin Oncol200927223584359019487381
   PubMed Web of Science ®Google Scholar
• SternbergCNDavisIDMardiakJPazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trialJ Clin Oncol20102861061106820100962
   PubMed Web of Science ®Google Scholar
• WoodsBSHawkinsNScottDANetwork meta-analysis on the log-hazard scale, combining count and hazard ratio statistics accounting for multi-arm trials: a tutorialBMC Med Res Methodol2010105420537177
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet200737096052103211118156031
   PubMed Web of Science ®Google Scholar
• MotzerRJFiglinRAHutsonTESunitinib versus interferon-alfa (IFN-a) as first-line treatment of metastatic renal cell carcinoma (mRCC): Updated results and analysis of prognostic factors: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2007 Jun 1–5J Clin Oncol20072518S502417971603
   PubMed Web of Science ®Google Scholar
• BucherHCGuyattGHGriffithLEWalterSDThe results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trialsJ Clin Epidemiol19975066836919250266
   PubMed Web of Science ®Google Scholar
• WellsGASultanSAChenLKhanMCoyleDIndirect evidence: indirect treatment comparisons in meta-analysis2009 Available from: http://www.cadth.ca/index.php/en/hta/reports-publications/search/publication/884. Accessed 2010 Dec 6.
   Google Scholar
• SongFAltmanDGGlennyAMDeeksJJValidity of indirect comparison for estimating efficacy of competing interventions: empirical evidence from published meta-analysesBMJ2003326738747212609941
   PubMed Web of Science ®Google Scholar
• TudurCWilliamsonPRKhanSBestLYThe value of the aggregate data approach in meta-analysis with time-to-event outcomesJ Royal Stat Soc20021642357370
   Google Scholar
• Medical Research Council Renal Cancer CollaboratorsInterferon-alpha and survival in metastatic renal carcinoma: early results of a randomised controlled trialLancet19993539146141710023944
   PubMed Web of Science ®Google Scholar
• AassNde MulderPHMickischGHRandomized phase II/III trial of interferon alfa-2a with and without 13-cis-retinoic acid in patients with progressive metastatic renal cell carcinoma: the European Organisation for Research and Treatment of Cancer Genitourinary Tract Cancer Group (EORTC 30951)J Clin Oncol200523184172417815961764
   PubMed Web of Science ®Google Scholar
• MickischGHGarinAvanPHde PrijckLSylvesterRRadical nephrectomy plus interferon-alfa-based immunotherapy compared with interferon alfa alone in metastatic renal-cell carcinoma: a randomised trialLancet2001358928696697011583750
   PubMed Web of Science ®Google Scholar
• SnedecorGWCochranWGTests of hypothesesStatistical Methods8th edAmes, IAIowa State University Press19896482
   Google Scholar
• WellsGASultanSAChenLKhanMCoyleDIndirect treatment comparison software application (version 1.0)2009 Available from: http://www.cadth.ca/index.php/en/itc-user-guide/download-software. Accessed 2010 Jul 20.
   Google Scholar
• MelicharBKoralewskiPRavaudAFirst-line bevacizumab combined with reduced dose interferon-alpha2a is active in patients with metastatic renal cell carcinomaAnn Oncol20081981470147618408224
   PubMed Web of Science ®Google Scholar
• CoppinCLeLPorzsoltFWiltTTargeted therapy for advanced renal cell carcinomaCochrane Database Syst Rev20082CD00601718425931
   PubMedGoogle Scholar
• MillsEJRachlisBO’ReganCThabaneLPerriDMetastatic renal cell cancer treatments: an indirect comparison meta-analysisBMC Cancer200993419173737
   PubMed Web of Science ®Google Scholar
• Thompson CoonJSLiuZHoyleMSunitinib and bevacizumab for first-line treatment of metastatic renal cell carcinoma: a systematic review and indirect comparison of clinical effectivenessBr J Cancer2009101223824319568242
   PubMed Web of Science ®Google Scholar
• RiniBIHalabiSRosenbergJEBevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206J Clin Oncol200826335422542818936475
   PubMed Web of Science ®Google Scholar
• GoreMEPortaCOudardSSunitinib in metastatic renal cell carcinoma (mRCC): Preliminary assessment of toxicity in an expanded access trial with subpopulation analysis: Proceedings of the American Society of Clinical Oncology (ASCO) Annual Meeting Chicago, IL, 2007 Jun 1–5J Clin Oncol20072518S5010
   Google Scholar
• GoreMESzczylikCPortaCSafety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trialLancet Oncol200910875776319615940
   PubMed Web of Science ®Google Scholar
• McCannLAmitOPanditeLAmadoRAn indirect comparison analysis of pazopanib versus other agents in metastatic renal cell carcinoma (mRCC)Proceedings of the American Society of Clinical Oncology (ASCO) Genitourinary Cancers SymposiumSan Francisco, CA2010 Mar 5–7 [Suppl; abstr # 413].
   Google Scholar
• PortaCBellmuntJEisenTSzczylikCMuldersPTreating the individual: The need for a patient-focused approach to the management of renal cell carcinomaCancer Treat Rev2010361162319819078
   PubMed Web of Science ®Google Scholar
• ProcopioGVerzoniEBajettaECosts of managing side effects in the treatment of first line metastatic renal cell carcinoma in Italy: Bevacizumab + Interferon alpha2a compared with Sunitinib: Proceedings of the European Society for Medical Oncology (ESMO) Congress, Stockholm, Sweden, 2008 Sep 12–16Ann Oncol2008198601P
   Google Scholar
• MickischGGoreMEscudierBProcopioGWalzerSNuijtenMCosts of managing adverse events in the treatment of first-line metastatic renal cell carcinoma: bevacizumab in combination with interferon-alpha2a compared with sunitinibBr J Cancer20101021808619920817
   PubMed Web of Science ®Google Scholar
• BracardaSBellmuntJNegrierSWhat is the impact of subsequent antineoplastic therapy on overall survival (OS) following first-line bevacizumab (BEV)/interferon-alpha2a (IFN) in metastatic renal cell carcinoma (mRCC)? Experience from AVOREN: Proceedings of the European Society for Medical Oncology (ESMO) Multidisciplinary Congress, Berlin, Germany, 2009 Sep 20–24Eur J Cancer200972P7126
   Google Scholar
• MelicharBHow can second-line therapy for metastatic renal cell carcinoma help to define an overall management strategy?Oncology2009772829119602908
   PubMed Web of Science ®Google Scholar
• EscudierBGoupilMGMassardCFizaziKSequential therapy in renal cell carcinomaCancer200911510 Suppl2321232619402067
   PubMed Web of Science ®Google Scholar